Interleukin-6 (IL-6) Inhibitors Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Tocilizumab, Siltuximab, and Sylvant); By Disease Type; By Distribution Channel; By Region; Segment Forecast, 2023-2032
- Published Date:Aug-2023
- Pages: 118
- Format: PDF
- Report ID: PM3720
- Base Year: 2022
- Historical Data: 2019-2021
Report Outlook
The global interleukin-6 (IL-6) inhibitors market was valued at USD 32.03 billion in 2022 and is expected to grow at a CAGR of 10.4% during the forecast period.
Development in the industry's clinical trials is one factor promoting the market's expansion worldwide. Clinical trials evaluate the safety and efficacy of IL-6 inhibitors in various medical conditions. These trials provide scientific evidence regarding the benefits and risks of IL-6 inhibitors, helping to establish their effectiveness in specific indications. For example, in June 2023, In Phase I research, the tocilizumab biosimilar candidate from Dr. Reddy's Laboratories, a multinational pharmaceutical business, fulfilled its primary and secondary goals. Increased awareness and understanding of the benefits and indications of IL-6 inhibitors can drive demand and adoption in clinical practice, fostering market growth. Therefore, clinical trials provide scientific evidence, expand indications, inform treatment guidelines, and contribute to the overall body of knowledge surrounding IL-6 inhibitors.
 Inhibitors Market.png)
To Understand More About this Research: Request a Free Sample Report
Interleukin-6 (IL-6) inhibitors are a class of medications used to block the action of IL-6, a cytokine (cell-signaling protein) involved in the inflammatory response. IL-6 inhibitors have various uses and applications in treating different medical conditions. It has also been approved for the treatment of certain forms of juvenile idiopathic arthritis, a chronic autoimmune joint disease that affects children and adolescents. These inhibitors can improve symptoms and quality of life in pediatric patients with Juvenile Idiopathic Arthritis. IL-6 inhibitors, such as tocilizumab and sarilumab, are approved for treating moderate to severe rheumatoid arthritis.
IL-6 inhibitors have been investigated as a potential treatment option for severe cases of COVID-19. These inhibitors block the action of IL-6, a cytokine involved in the inflammatory response. As a result, there has been increased demand for IL-6 inhibitors in treating COVID-19, leading to a surge in their market. The pandemic has also redirected research and development (R&D) efforts toward understanding the immunopathology of the disease and developing effective treatments.
Moreover, the COVID-19 pandemic has prompted numerous clinical trials and research studies focusing on IL-6 inhibitors. These studies aim to evaluate the effectiveness of IL-6 inhibitors in managing COVID-19-related inflammation and improving patient outcomes. For example, on December 21, 2022, the IV tocilizumab to treat COVID-19 hospitalized adults who are receiving systemic corticosteroids and need supplemental oxygen, non-invasive ventilation (NIV), or extracorporeal membrane oxygenation (ECMO) was authorized by the FDA. The increased research activity has contributed to scientific knowledge and driven the market for IL-6 inhibitors.
 Inhibitors Market New.png)
For Specific Research Requirements, Request for a Sample Report
Industry Dynamics
Growth Drivers
High popularity of interleukin-6 inhibitor
The high popularity of interleukin-6 inhibitors during the pandemic is another growth aspect escalating the development of the market globally. The demand for IL-6 inhibitors in the context of COVID-19 has prompted manufacturers to increase production and ensure sufficient supply. For instance, in March 2020, the approved arthritis medicine Kevzara is being tested in a Phase II/III trial program in the U.S. to treat severe COVID infection in up to 400 patients, according to Regeneron Pharmaceuticals & Sanofi. IL-6 receptor antagonist Kevzara was given FDA approval in 2017 to treat individuals with moderately to severe rheumatoid arthritis who had poor treatment or intolerance to more disease-modifying anti-rheumatic medications. Such developments in COVID-19 treatments and the changing landscape of the pandemic have impacted the market worldwide.
Support from various agencies, organizations, and institutes is significantly assisting the market to boom rapidly. Regulatory agencies like the U.S. FDA & EMA have granted emergency use authorizations and approvals for IL-6 inhibitors in treating severe COVID-19 cases. For example, the World Health Organisation (WHO) has modified its patient treatment recommendations to include interleukin-6 receptor blockers, a family of drugs that can save the lives of COVID-19 patients who are critically ill or seriously unwell, especially when given in conjunction with corticosteroids. These regulatory decisions have facilitated using IL-6 inhibitors as a therapeutic option. This is further leading to augmented demand and market growth globally.
Report Segmentation
The market is primarily segmented based on drug type, disease type, distribution channel, and region.
|
By Drug Type |
By Disease type |
By Distribution Channel |
By Region |
|
|
|
|
To Understand the Scope of this Report: Speak to Analyst
By Drug Type
Tocilizumab segment dominated the market in 2022
The tocilizumab segment dominated the market in 2022 as it was one of the first IL-6 inhibitors to receive regulatory approval and enter the market. Its early entry provided a competitive advantage and established it as a well-known and widely used IL-6 inhibitor. Also, it has received approvals for multiple indications, including rheumatologic conditions and CRS associated with CAR-T cell therapy. Its broad spectrum of indications has contributed to its market dominance by addressing a range of patient needs.
Moreover, tocilizumab has demonstrated its efficacy and safety in various clinical trials across different indications. Positive clinical data and real-world evidence have supported its widespread adoption and use. For example, in December 2022, the FDA approved Actemra IV to treat COVID patients who are receiving systemic corticosteroids requiring supplemental oxygen, non-invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO), according to a statement from Genentech, a member of the Roche Group.
By Disease Type
Rheumatoid arthritis held the largest global share in 2022
In 2022, the rheumatoid arthritis segment held the largest global share in volume and value. It is a chronic autoimmune disease that affects the joints, causing inflammation, pain, stiffness, and functional disability, particularly tocilizumab have gained widespread acceptance among rheumatologists and other healthcare professionals as an important treatment option for rheumatoid arthritis. IL-6 inhibitors have demonstrated efficacy in managing the signs and symptoms of rheumatoid arthritis, including reducing joint inflammation, improving physical function, and preventing joint damage.
By Distribution Channel
Specialty pharmacies segment held largest share of the global revenue in 2022
The specialty pharmacies segment held the largest revenue share in 2022. Specialty pharmacies are a key distribution channel for IL-6 inhibitors. These pharmacies specialize in providing medications for complex and chronic diseases, including rheumatoid arthritis and other conditions treated with IL-6 inhibitors. Specialty pharmacies often have the necessary infrastructure and expertise to handle the storage, handling, and distribution of specialty biologic medications like IL-6 inhibitors.
Regional Analysis
North America is anticipated to dominate the global market during projected period
North America is expected to lead the global market in the upcoming years. This is primarily due to the largely increasing prevalence of rheumatoid arthritis (RA) in the region. For example, according to a US study, women experience a higher annual incidence of RA than men. The American College of Rheumatology states that RA is the most prevalent type of autoimmune arthritis. In the United States, 1.3 million people have RA or 0.6 to 1% of the population. The high disease burden of RA creates a strong demand for effective treatments like IL-6 inhibitors, which can help manage the symptoms and slow down the progression of the disease. The high prevalence of rheumatoid arthritis, coupled with the limited efficacy of conventional therapies and the shift towards targeted biologic treatments, drives the demand for IL-6 inhibitors in the market across the North American region.
Europe is another major contributor to the growth of the IL-6 inhibitors market, with a considerable share. The region is known for its well-established healthcare infrastructure, which includes advanced medical facilities, research institutions, and a robust regulatory framework. For instance, Germany has a strong healthcare system, particularly regarding hospital beds, infrastructure, and skilled personnel. This infrastructure supports developing clinical trials and adopting innovative therapies like IL-6 inhibitors. The presence of specialized rheumatology centers and expert healthcare professionals further contributes to the region’s growth.
Competitive Insight
The Interleukin-6 (IL-6) Inhibitors market is fragmented and is anticipated to witness competition due to several players' presence. Major service providers in the market are constantly upgrading their technologies to stay ahead of the competition and to ensure efficiency, integrity, and safety. These players focus on partnership, product upgrades, and collaboration to gain a competitive edge over their peers and capture a significant market share.
Some of the major players operating in the global market include:
- AbbVie
- AstraZeneca
- Bausch Health
- Eli Lilly
- GlaxoSmithKline
- Johnson and Johnson Services
- Novartis
- Regeneron Pharmaceuticals
- Roche
- Teva Pharmaceutical.
Recent Developments
- In December 2021, SYLVANT, also known as idiopathic MCD (iMCD), has been approved by the China National Medical Products Administration (NMPA) for the treatment of adult patients with multi-centric Castleman disease (MCD), also known as the idiopathic MCD (iMCD), who are HIV- & HHV-8-negative.
Interleukin-6 (IL-6) Inhibitors Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2023 |
USD 35.31 billion |
|
Revenue forecast in 2032 |
USD 86.31 billion |
|
CAGR |
10.4% from 2023 – 2032 |
|
Base year |
2022 |
|
Historical data |
2019– 2021 |
|
Forecast period |
2023– 2032 |
|
Quantitative units |
Revenue in USD billion and CAGR from 2023 to 2032 |
|
Segments covered |
By Drug Type, By Disease Type, By Distribution Channel, By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America; Middle East & Africa |
|
Customization |
Report customization as per your requirements with respect to countries, region and segmentation. |
FAQ's
key companies in interleukin-6 (IL-6) inhibitors market are AbbVie, AstraZeneca, Bausch Health, Eli Lilly, GlaxoSmithKline.
The global interleukin-6 (IL-6) inhibitors market is expected to grow at a CAGR of 10.4% during the forecast period.
The interleukin-6 (IL-6) inhibitors market report covering key segments are drug type, disease type, distribution channel, and region.
key driving factors in interleukin-6 (IL-6) inhibitors market are high popularity of interleukin-6 inhibitor.
The global interleukin-6 (IL-6) inhibitors market size is expected to reach USD 86.31 billion by 2032.
